In Part 1 of this "Mini Grand Rounds" series, we discuss Angiotensin II use for vasodilatory shock, reviewing the ATHOS-3 trial and real-world experiences.

References:

Khanna A, English SW, Wang XS, et al. Angiotensin II for the treatment of vasodilatory shock. NEJM. 2017; 377: 419-430

Farina N, Bixby A, Alaniz C. Angiotensin II brings more questions than answers. P T. 2019; 43 (11): 685- 687

Disclaimer: 
The information contained within the  ER-Rx podcast episodes, errxpodcast.com, and the @errxpodcast Instagram page is for informational/ educational purposes only, is not meant to replace professional medical judgement, and does not constitute a provider-patient relationship between you and the authors. Information contained herein may be accidentally inaccurate, incomplete, or outdated, and users are to use caution,  seek medical advice from a licensed physician,  and consult available resources prior to any medical decision making. The contributors of the ER-Rx podcast are not affiliated with, nor do they speak on behalf of,  any medical institutions, educational facilities, or other healthcare programs.

Support the show

Find ER-Rx:

- On Instagram: @ERRxPodcast
- On the website: errxpodcast.com
- On YouTube

Disclaimer:

The information contained within the ER-Rx podcast episodes, errxpodcast.com, and the @errxpodcast Instagram page is for informational/ educational purposes only, is not meant to replace professional medical judgement, and does not constitute a provider-patient relationship between you and the authors. Information contained herein may be accidentally inaccurate, incomplete, or outdated, and users are to use caution, seek medical advice from a licensed physician, and consult available resources prior to any medical decision making. The contributors of the ER-Rx podcast are not affiliated with, nor do they speak on behalf of, any medical institutions, educational facilities, or other healthcare programs.